NEW YORK (GenomeWeb) – Sygnis today announced a non-exclusive distribution agreement with Sopachem for the commercialization of TruePrime products.

Under the terms of the agreement, Sopachem will promote, market, sell, and support TruePrime products for primer-free whole genome amplification in Belgium.

TruePrime products use Sygnis' multiple displacement amplification technology based on DNA primase TthPrimPol and Phi29 polymerase.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.